Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Torrent Pharma net profit up 18 percent at Rs 297 crore in Q3

Ruchika Sharma10 Feb 2021 10:00 AM IST

New Delhi: Drug firm Torrent Pharmaceuticals on Monday reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the...

Indian pharma industry expected to reach USD 130 billion by 2030: D V Sadananda Gowda

Ruchika Sharma9 Feb 2021 1:12 PM IST

At the year''s edition, "we would like to deliberate upon strategies to help us innovate and bring newer and affordable therapies to the market and...

Advent International to acquire controlling stake in ZCL Chemicals at Rs 1,700 crore enterprise value

Ruchika Sharma9 Feb 2021 12:45 PM IST

Mumbai: Private equity fund Advent International will acquire a controlling stake in pharmaceutical company ZCL Chemicals for an enterprise value...

NPPA fixed price of 8 formulations including FDCs of Statins, Glifozins

Ruchika Sharma9 Feb 2021 12:37 PM IST

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority, the pharma price regulator has fixed the price of 8...

$Rhizen Pharma gets USFDA accelerated nod for Partnered asset Umbralisib adult patients with Relapsed or Refractory MZL & FL$

Rhizen Pharma gets USFDA accelerated nod for Partnered asset Umbralisib adult patients with Relapsed or Refractory MZL & FL

Ruchika Sharma9 Feb 2021 12:04 PM IST

Basel, Switzerland: Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, has recently announced that the company's...

Entresto Patent Expiry to Weigh on Novartis as Profit Seen Falling in 2026

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok

Articles By : Ruchika Sharma

Torrent Pharma net profit up 18 percent at Rs 297 crore in Q3

Indian pharma industry expected to reach USD 130 billion by 2030: D V Sadananda Gowda

Advent International to acquire controlling stake in ZCL Chemicals at Rs 1,700 crore enterprise value

NPPA fixed price of 8 formulations including FDCs of Statins, Glifozins

Rhizen Pharma gets USFDA accelerated nod for Partnered asset Umbralisib adult patients with Relapsed or Refractory MZL & FL

Novartis gets USFDA Breakthrough Therapy designations for STAMP inhibitor asciminib to treat chronic myeloid leukemia

Fortis Healthcare reports Rs 53.88 crore net profit for December quarter

AstraZeneca COVID-19 vaccine less effective against South African strain, claims study

AstraZeneca gets DCGI nod for Dapagliflozin tablets to treat chronic kidney disease

Sun Pharma recalls 36,275 cartons of Testosterone Cypionate Injection in US over incorrect labelling

Zydus Cadila net profit rises 41 percent to Rs 527 crore in Q3

Indian Pharma exports grew by 12.43 percent to USD 17.57 billion during Apr-Dec 2021